MCID: PRV006
MIFTS: 53

Pervasive Developmental Disorder malady

Categories: Mental diseases

Aliases & Classifications for Pervasive Developmental Disorder

Aliases & Descriptions for Pervasive Developmental Disorder:

Name: Pervasive Developmental Disorder 12 52 14
Pervasive Development Disorder 12 69
Pervasive Developmental Disorders 51
Autism Spectrum Disorders 69
Autistic Behavior 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060040
ICD9CM 35 299.80
ICD10 33 F84
UMLS 69 C0154451

Summaries for Pervasive Developmental Disorder

NINDS : 51 The diagnostic category of pervasive developmental disorders (PDD) refers to a group of disorders characterized by delays in the development of socialization and communication skills. Parents may note symptoms as early as infancy, although the typical age of onset is before 3 years of age. Symptoms may include problems with using and understanding language; difficulty relating to people, objects, and events; unusual play with toys and other objects; difficulty with changes in routine or familiar surroundings, and repetitive body movements or behavior patterns. Autism (a developmental brain disorder characterized by impaired social interaction and communication skills, and a limited range of activities and interests) is the most characteristic and best studied PDD. Other types of PDD include Asperger's Syndrome, Childhood Disintegrative Disorder, and Rett's Syndrome. Children with PDD vary widely in abilities, intelligence, and behaviors. Some children do not speak at all, others speak in limited phrases or conversations, and some have relatively normal language development. Repetitive play skills and limited social skills are generally evident. Unusual responses to sensory information, such as loud noises and lights, are also common.

MalaCards based summary : Pervasive Developmental Disorder, also known as pervasive development disorder, is related to autism spectrum disorder and schizophrenia, and has symptoms including fatigue, sleep disturbances and photophobia. An important gene associated with Pervasive Developmental Disorder is MECP2 (Methyl-CpG Binding Protein 2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Aripiprazole and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A developmental disorder of mental health that refers to a group of five disorders characterized by impairments in socialization and communication, as well as restricted interests and repetitive behaviors.

Wikipedia : 71 The diagnostic category pervasive developmental disorders (PDD), as opposed to specific developmental... more...

Related Diseases for Pervasive Developmental Disorder

Diseases related to Pervasive Developmental Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
id Related Disease Score Top Affiliating Genes
1 autism spectrum disorder 31.9 FMR1 FOXP2 MECP2 OXT SHANK3 SLC6A4
2 schizophrenia 29.8 CNTNAP2 GABRB3 NRXN1 OXTR RELN SHANK3
3 pervasive developmental disorder not otherwise specified 12.4
4 atypical autism 11.3
5 landau-kleffner syndrome 11.3
6 childhood disintegrative disease 11.2
7 asperger syndrome 11.2
8 autism susceptibility, x-linked 2 11.0
9 autism x-linked 4 11.0
10 autism susceptibility 16 11.0
11 autism susceptibility, x-linked 1 11.0
12 autism susceptibility, x-linked 3 11.0
13 autism x-linked 5 11.0
14 epsilon-trimethyllysine hydroxylase deficiency 11.0
15 autism susceptibility 15 11.0
16 autism susceptibility 17 11.0
17 autism 18 11.0
18 autism 9 10.9
19 autism 10 10.9
20 autistic disorder 10.9
21 specific developmental disorder 10.8
22 potocki-lupski syndrome 10.8
23 mental retardation, autosomal recessive 41 10.8
24 autism 19 10.8
25 potocki-luspski syndrome 10.8
26 chromosome 16p11.2 deletion syndrome, 220-kb body mass index quantitative trait locus 16, included 10.8
27 rett syndrome 10.8
28 attention deficit-hyperactivity disorder 10.4
29 epilepsy 10.3
30 munchausen by proxy 10.2 NLGN3 NLGN4X OXTR
31 plasma cell leukemia 10.2 CNTNAP2 NRXN1
32 cholesterol pneumonia 10.2 CNTNAP2 FOXP2
33 carnosinemia 10.1 CDKL5 CNTNAP2 NRXN1
34 immunodeficiency, isolated 10.1 FMR1 MECP2 SLC6A4
35 angina pectoris 10.1 CNTNAP2 FOXP2 MECP2 TOR3A
36 encephalopathy, neonatal severe 10.1 CDKL5 GABRB3 MECP2 SHANK3
37 bipolar disorder 10.1
38 mental retardation, autosomal dominant 26 10.0
39 brugada syndrome 10.0 GABRB3 NLGN3 NLGN4X OXTR SHANK3 SLC6A4
40 colitis 10.0
41 chronic conjunctivitis 10.0 GABRB3 OXT RELN SHANK3 SLC6A4
42 ellis-van creveld syndrome 10.0 CNTNAP2 FMR1 MECP2 SLC6A4
43 pandas 9.9
44 intellectual disability 9.9
45 anxiety disorder 9.9
46 angelman syndrome 9.8
47 cerebritis 9.8
48 pancreatitis 9.8
49 influenza 9.8
50 aphasia 9.8

Graphical network of the top 20 diseases related to Pervasive Developmental Disorder:



Diseases related to Pervasive Developmental Disorder

Symptoms & Phenotypes for Pervasive Developmental Disorder

UMLS symptoms related to Pervasive Developmental Disorder:


fatigue, sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

MGI Mouse Phenotypes related to Pervasive Developmental Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 CDKL5 CNTNAP2 FMR1 GABRB3 MECP2 NLGN3
2 growth/size/body region MP:0005378 10.13 CNTNAP2 FMR1 GABRB3 MECP2 NLGN3 NRXN1
3 nervous system MP:0003631 10.03 SHANK2 SHANK3 SLC6A4 TBX1 TDO2 CDKL5
4 integument MP:0010771 9.96 CNTNAP2 FMR1 MECP2 OXT OXTR RELN
5 no phenotypic analysis MP:0003012 9.5 CDKL5 GABRB3 MECP2 NLGN3 OXTR SHANK2
6 taste/olfaction MP:0005394 8.92 CDKL5 CNTNAP2 NLGN3 SHANK3

Drugs & Therapeutics for Pervasive Developmental Disorder

Drugs for Pervasive Developmental Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 434)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
2
Valproic Acid Approved, Investigational Phase 4,Phase 2 99-66-1 3121
3
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
5
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19982-08-2 4054
6
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-56-6 439302 53477758
7
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
8
Milnacipran Approved Phase 4 92623-85-3 65833
9
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 3 132539-06-1 4585
10
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
11
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
12
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
13
Minocycline Approved, Investigational Phase 4,Phase 1 10118-90-8 5281021
14
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
15
Copper Approved Phase 4,Phase 1 15158-11-9, 7440-50-8 27099
16
Iron Approved Phase 4,Phase 2 7439-89-6 23925
17
Selenium Approved, Vet_approved Phase 4 7782-49-2
18
Amlodipine Approved Phase 4 88150-42-9 2162
19
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
20
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
21
Isoniazid Approved Phase 4 54-85-3 3767
22
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
23
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
24
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
25
Desoximetasone Approved Phase 4 382-67-2 5311067
26
Choline Approved, Nutraceutical Phase 4 62-49-7 305
27
Creatine Approved, Nutraceutical Phase 4 57-00-1 586
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
29
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
30
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
31
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
32
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 73-31-4 896
33 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
35 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Early Phase 1
36 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
37 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Antibodies Phase 4,Phase 2
39 gamma-Globulins Phase 4,Phase 2
40 Immunoglobulins Phase 4,Phase 2
41 Immunoglobulins, Intravenous Phase 4,Phase 2
42 Rho(D) Immune Globulin Phase 4,Phase 2
43 Anticonvulsants Phase 4,Phase 2,Phase 3
44 Antimanic Agents Phase 4,Phase 2
45 GABA Agents Phase 4,Phase 2
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 812)
id Name Status NCT ID Phase
1 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4
2 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4
3 Divalproex Sodium ER in Adult Autism Unknown status NCT00211796 Phase 4
4 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4
5 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4
6 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4
7 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
8 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4
9 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4
10 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4
11 Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Completed NCT02255565 Phase 4
12 Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism Completed NCT02235467 Phase 4
13 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4
14 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4
15 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4
16 Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Completed NCT01333072 Phase 4
17 Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study Completed NCT00352196 Phase 4
18 Minocycline to Treat Childhood Regressive Autism Completed NCT00409747 Phase 4
19 A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder Completed NCT00576732 Phase 4
20 Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder Completed NCT01227668 Phase 4
21 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4
22 A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent Completed NCT00825279 Phase 4
23 Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months Completed NCT02280330 Phase 4
24 Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy Completed NCT00351130 Phase 4
25 Antibiotics and Gut Microbiota Among Newborn Infants Completed NCT02072798 Phase 4
26 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
27 Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Recruiting NCT02096952 Phase 4
28 Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters Recruiting NCT02708901 Phase 4
29 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Recruiting NCT01098383 Phase 4
30 Evaluating Treatment Resistant Dermatitis TaroIIR Recruiting NCT03050294 Phase 4
31 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Recruiting NCT02346149 Phase 4
32 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Active, not recruiting NCT01339858 Phase 4
33 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Enrolling by invitation NCT02940574 Phase 4
34 Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Terminated NCT01033565 Phase 4
35 Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders Unknown status NCT01243905 Phase 2, Phase 3
36 Oxytocin in Adolescents With Autism Spectrum Disorders Unknown status NCT02007447 Phase 2, Phase 3
37 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3
38 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
39 Local Endometrial Injury in Fresh Embryo Transfer Cycles Unknown status NCT01844453 Phase 3
40 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3
41 D-Cycloserine and Social Skills Training in Autism Spectrum Disorders Completed NCT01086475 Phase 3
42 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) Completed NCT00261508 Phase 3
43 Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Completed NCT02081027 Phase 2, Phase 3
44 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed NCT01825798 Phase 3
45 Understanding Sleep Problems in Children With Autism Spectrum Disorder Completed NCT00691080 Phase 2, Phase 3
46 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
47 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
48 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00352352 Phase 3
49 Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder Completed NCT00352248 Phase 3
50 Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation Completed NCT00355329 Phase 3

Search NIH Clinical Center for Pervasive Developmental Disorder

Genetic Tests for Pervasive Developmental Disorder

Anatomical Context for Pervasive Developmental Disorder

MalaCards organs/tissues related to Pervasive Developmental Disorder:

39
Brain, Testes, Heart, Skin, Eye, Cortex, Prefrontal Cortex

Publications for Pervasive Developmental Disorder

Articles related to Pervasive Developmental Disorder:

(show top 50) (show all 262)
id Title Authors Year
1
Are There Differences in Neurocognition and Social Cognition Among Adolescents with Schizophrenia, a Pervasive Developmental Disorder, and Both Disorders? ( 27015370 )
2016
2
Autism Spectrum/Pervasive Developmental Disorder. ( 27262008 )
2016
3
A Prospective Longitudinal Assessment of Medical Records for Diagnostic Substitution among Subjects Diagnosed with a Pervasive Developmental Disorder in the United States. ( 26528457 )
2015
4
The Stability of Comorbid Psychiatric Disorders: A 7A Year Follow Up of Children with Pervasive Developmental Disorder-Not Otherwise Specified. ( 26456972 )
2015
5
Hemispheric Processing of Idioms and Irony in Adults With and Without Pervasive Developmental Disorder. ( 26070277 )
2015
6
Psychiatric comorbidity in children with high-functioning pervasive developmental disorder. ( 25272562 )
2014
7
Sunsetting DSM-IV's pervasive developmental disorder. ( 24745948 )
2014
8
Psychological interventions in pervasive developmental disorder: An overview. ( 25788797 )
2014
9
Examining the criterion-related validity of the Pervasive Developmental Disorder Behavior Inventory. ( 24463433 )
2014
10
Detecting Subgroups in Children Diagnosed with Pervasive Developmental Disorder - Not Otherwise Specified. ( 25374133 )
2014
11
A Case-Control Study Evaluating the Relationship Between Thimerosal-Containing Haemophilus influenzae Type b Vaccine Administration and the Risk for a Pervasive Developmental Disorder Diagnosis in the United States. ( 25382662 )
2014
12
Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( 24703761 )
2014
13
A comparison of DSM-IV pervasive developmental disorder and DSM-5 autism spectrum disorder prevalence in an epidemiologic sample. ( 24745950 )
2014
14
Sensory hypersensitivity in children with high-functioning pervasive developmental disorder. ( 25803881 )
2014
15
Catatonic features in adolescents with schizophrenia with and without a comorbid pervasive developmental disorder. ( 24914405 )
2014
16
Brief report: An unusual manifestation of diagnostic overshadowing of pervasive developmental disorder--not otherwise specified: a five year longitudinal case study. ( 23108987 )
2013
17
Diagnostic Boundaries of Autism Disorder Vs Pervasive Developmental Disorder Nos: Comparative Observational Study and Literature Review. ( 24050746 )
2013
18
Comparison of pervasive developmental disorder and schizophrenia by the Japanese version of the National Adult Reading Test. ( 22335467 )
2013
19
Pervasive developmental disorder in the children of immigrant parents: comparison of different assessment instruments. ( 24394875 )
2013
20
Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. ( 24130822 )
2013
21
Dual copy number variants involving 16p11 and 6q22 in a case of childhood apraxia of speech and pervasive developmental disorder. ( 22909776 )
2013
22
Psychiatric diagnostic screening of social maladaptive behaviour in children with mild intellectual disability: differentiating disordered attachment and pervasive developmental disorder behaviour. ( 23906477 )
2013
23
Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study. ( 23782127 )
2013
24
Inhibitory function and working memory in attention deficit/hyperactivity disorder and pervasive developmental disorders: does a continuous cognitive gradient explain ADHD and PDD traits? ( 24145729 )
2013
25
Anxiety in children with high-functioning pervasive developmental disorder. ( 23909078 )
2013
26
Reduced brain activation during imitation and observation of others in children with pervasive developmental disorder: a pilot study. ( 23718943 )
2013
27
Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. ( 23468071 )
2013
28
Sexual obsessions, compulsions, suicidality and homicidality in an adolescent diagnosed with bipolar disorder not otherwise specified, obsessive-compulsive disorder, pervasive developmental disorder not otherwise specified, and mild mental retardation. ( 22612525 )
2012
29
Is recovery from a pervasive developmental disorder possible? ( 22353321 )
2012
30
Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. ( 23032385 )
2012
31
Executive function in children with pervasive developmental disorder and attention-deficit/hyperactivity disorder assessed by the Keio version of the Wisconsin card sorting test. ( 21917389 )
2012
32
Multi-channel near-infrared spectroscopy shows reduced activation in the prefrontal cortex during facial expression processing in pervasive developmental disorder. ( 22250607 )
2012
33
A case of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) coexisting with pervasive developmental disorder harboring SCN1A mutation in addition to CHRNB2 mutation. ( 23032131 )
2012
34
Impact of attention deficit hyperactivity disorder-like symptoms on the clinical features of adolescents with pervasive developmental disorders. ( 23857705 )
2012
35
Novel AGTR2 missense mutation in a Japanese boy with severe mental retardation, pervasive developmental disorder, and epilepsy. ( 22269148 )
2012
36
Using virtual reality environment to improve joint attention associated with pervasive developmental disorder. ( 22776822 )
2012
37
Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. ( 23194148 )
2012
38
Focal EEG abnormalities might reflect neuropathological characteristics of pervasive developmental disorder and attention-deficit/hyperactivity disorder. ( 22225922 )
2012
39
Is long-term prognosis for pervasive developmental disorder not otherwise specified different from prognosis for autistic disorder? Findings from a 30-year follow-up study. ( 21713590 )
2012
40
Retrospective case report: evaluation of pain in a child with pervasive developmental disorder. ( 21552087 )
2011
41
Brief report: prevalence of pervasive developmental disorder in Brazil: a pilot study. ( 21337063 )
2011
42
Epilepsy in pervasive developmental disorder without brain MRI abnormalities. ( 20863637 )
2011
43
Buspirone for bruxism in a child with pervasive developmental disorder-not otherwise specified. ( 22136097 )
2011
44
The relationship between race and challenging behaviours in infants and toddlers with autistic disorder and pervasive developmental disorder-not otherwise specified. ( 21732805 )
2011
45
A case of pervasive developmental disorder complicated by social anxiety disorder responding well to fluvoxamine therapy. ( 21769772 )
2011
46
Analysis of Copper and Zinc Plasma Concentration and the Efficacy of Zinc Therapy in Individuals with Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and Autism. ( 22174567 )
2011
47
The specific impairment of fearful expression recognition and its atypical development in pervasive developmental disorder. ( 21919566 )
2011
48
Effectiveness of modified parent training for mothers of children with Pervasive Developmental Disorder on parental confidence and children's behavior. ( 20385459 )
2011
49
Is pervasive developmental disorder not otherwise specified less stable than autistic disorder? A meta-analysis. ( 21153874 )
2011
50
New onset of psychotic symptoms in an adolescent with pervasive developmental disorder, not otherwise specified. ( 21309699 )
2011

Variations for Pervasive Developmental Disorder

Expression for Pervasive Developmental Disorder

Search GEO for disease gene expression data for Pervasive Developmental Disorder.

Pathways for Pervasive Developmental Disorder

GO Terms for Pervasive Developmental Disorder

Cellular components related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.71 FMR1 SHANK2 SHANK3 SLC6A4
2 cell junction GO:0030054 9.7 FMR1 GABRB3 NLGN3 NLGN4X NRXN1 SHANK2
3 postsynaptic density GO:0014069 9.62 FMR1 NLGN4X SHANK2 SHANK3
4 dendritic spine GO:0043197 9.54 FMR1 SHANK2 SHANK3
5 postsynapse GO:0098794 9.43 FMR1 MECP2 NLGN3
6 postsynaptic membrane GO:0045211 9.35 FMR1 GABRB3 NLGN4X SHANK2 SHANK3
7 synapse GO:0045202 9.17 CDKL5 FMR1 GABRB3 NLGN3 NLGN4X NRXN1

Biological processes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 48)
id Name GO ID Score Top Affiliating Genes
1 synapse assembly GO:0007416 9.88 MECP2 NLGN3 NRXN1 SHANK2 SHANK3
2 response to estradiol GO:0032355 9.87 OXT OXTR SLC6A4
3 positive regulation of synapse assembly GO:0051965 9.85 MECP2 NLGN3 NRXN1 OXT OXTR
4 memory GO:0007613 9.85 MECP2 OXT OXTR SHANK2 SHANK3 SLC6A4
5 cerebral cortex development GO:0021987 9.83 CNTNAP2 FOXP2 RELN
6 long-term synaptic potentiation GO:0060291 9.83 MECP2 NLGN3 RELN SHANK2 SHANK3
7 cerebellum development GO:0021549 9.8 FOXP2 MECP2 NLGN4X
8 positive regulation of excitatory postsynaptic potential GO:2000463 9.8 NLGN3 NRXN1 RELN SHANK3
9 adult behavior GO:0030534 9.8 CNTNAP2 NLGN3 NLGN4X NRXN1 SHANK2 SHANK3
10 positive regulation of dendritic spine development GO:0060999 9.76 CDKL5 FMR1 SHANK3
11 regulation of N-methyl-D-aspartate selective glutamate receptor activity GO:2000310 9.75 NLGN3 NRXN1 RELN
12 neuron cell-cell adhesion GO:0007158 9.74 NLGN3 NLGN4X NRXN1
13 presynaptic membrane assembly GO:0097105 9.73 NLGN3 NLGN4X NRXN1
14 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.73 NLGN3 NRXN1 OXTR RELN SHANK2 SHANK3
15 sperm ejaculation GO:0042713 9.71 OXT OXTR SLC6A4
16 vocal learning GO:0042297 9.71 CNTNAP2 FOXP2 NRXN1 SHANK3
17 brain morphogenesis GO:0048854 9.7 SHANK3 SLC6A4
18 long term synaptic depression GO:0060292 9.7 SHANK2 SHANK3
19 regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity GO:2000311 9.7 NLGN3 NRXN1
20 NMDA glutamate receptor clustering GO:0097114 9.7 NRXN1 RELN SHANK3
21 exploration behavior GO:0035640 9.69 SHANK2 SHANK3
22 regulation of dendritic spine morphogenesis GO:0061001 9.69 NLGN3 SHANK3
23 positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity GO:2000969 9.69 NLGN3 RELN SHANK3
24 positive regulation of long-term synaptic potentiation GO:1900273 9.68 RELN SHANK3
25 thalamus development GO:0021794 9.68 CNTNAP2 SLC6A4
26 maternal behavior GO:0042711 9.68 OXT OXTR
27 protein localization to synapse GO:0035418 9.68 NRXN1 RELN
28 regulation of respiratory gaseous exchange by neurological system process GO:0002087 9.67 MECP2 NLGN3
29 sleep GO:0030431 9.67 OXT OXTR
30 positive regulation of synapse maturation GO:0090129 9.67 NRXN1 RELN
31 receptor localization to synapse GO:0097120 9.66 NRXN1 RELN
32 negative regulation of excitatory postsynaptic potential GO:0090394 9.65 NLGN3 NLGN4X
33 positive regulation of uterine smooth muscle contraction GO:0070474 9.65 OXT OXTR
34 inhibitory postsynaptic potential GO:0060080 9.65 GABRB3 NLGN3
35 postsynaptic membrane assembly GO:0097104 9.64 NLGN3 NRXN1
36 postsynaptic density protein 95 clustering GO:0097119 9.64 NRXN1 RELN
37 regulation of long-term synaptic potentiation GO:1900271 9.63 NLGN3 SHANK3
38 vocalization behavior GO:0071625 9.63 CNTNAP2 NLGN3 NLGN4X NRXN1 SHANK2 SHANK3
39 regulation of grooming behavior GO:2000821 9.62 NRXN1 SHANK3
40 positive regulation of penile erection GO:0060406 9.62 OXT OXTR
41 positive regulation of norepinephrine secretion GO:0010701 9.61 OXT OXTR
42 negative regulation of gastric acid secretion GO:0060455 9.61 OXT OXTR
43 guanylate kinase-associated protein clustering GO:0097117 9.6 NRXN1 SHANK3
44 regulation of digestive system process GO:0044058 9.59 OXT OXTR
45 learning GO:0007612 9.56 CNTNAP2 MECP2 NLGN3 NLGN4X NRXN1 RELN
46 social behavior GO:0035176 9.36 CNTNAP2 MECP2 NLGN3 NLGN4X NRXN1 OXT
47 cell adhesion GO:0007155 10.1 CNTNAP2 NLGN3 NLGN4X NRXN1 RELN
48 brain development GO:0007420 10.02 CHD8 CNTNAP2 MECP2 RELN SCT SLC6A4

Molecular functions related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell adhesion molecule binding GO:0050839 9.33 NLGN3 NLGN4X NRXN1
2 neurexin family protein binding GO:0042043 9.32 NLGN3 NLGN4X
3 siRNA binding GO:0035197 9.26 FMR1 MECP2
4 scaffold protein binding GO:0097110 9.13 NLGN3 NLGN4X SHANK3
5 GKAP/Homer scaffold activity GO:0030160 8.62 SHANK2 SHANK3

Sources for Pervasive Developmental Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....